Effect of Calcium Channel Blockers on Lower Urinary Tract Symptoms: A Systematic Review
Table 1
Description of the five studies included in this systematic review of studies evaluating the relationship of calcium channel blockers with lower urinary tract symptoms.
Participants from The Boston Area Community Health Survey
= 1865, age 30–79 yrs (mean age: 55.2), 54% males
To examine differences in the prevalence of lower urinary tract symptom among users of five common antihypertensive medication classes compared with nonusers
Participants from a multicenter Japanese study on silodosin
= 3790, NR (mean age: 71.1), 100% males
The associations between male lower urinary tract symptoms and hypertension, and to examine whether antihypertensive medications, particularly Angiotensin-II receptor blockers, influence LUTS
Participants from longitudinal, community based Krimpen Study of male urogenital tract problems and general health status
= 1668, age 50–78 years old (mean age: 60.6), 100% males
To explore the risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging male